Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

DRAFFT 2 logo

The DRAFFT2 –Distal Radius Acute Fracture Fixation Trial 2 has now opened its first 2 sites for recruitment. Peterborough City Hospital and Royal Stoke University Hospital are now recruiting patients for the trial which is comparing two different ways of fixing bones within the broken wrist: K-wires and plaster cast.

Most fractures can be treated without the need for surgery. However, for the more serious wrist injuries, the treating surgeon may recommend an operation to restore the normal position of the wrist bones. This study is for patients who are having surgery for their broken wrist.

Both techniques are used routinely throughout the NHS, but we don’t know which one works best.

  • This is a multi-centre, multi-surgeon, parallel, two-arm, randomised controlled trial. It is planned to run across 16 sites in the UK and recruit 476 patients.
  • Patients over the age of 16 with a dorsally displaced fracture of the distal radius are potentially eligible for the trial.
  • We will ask all patients to report their own recovery using a questionnaire at 3 months, 6 months and 12 months after the treatment. The trial will also collect important information for secondary outcomes on quality of life, complications, resource use, costs and comparative cost effectiveness.

For more information and contacts, please visit https://www.ndorms.ox.ac.uk/clinical-trials/current-trials-and-studies/drafft-2

Similar stories

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Three NIHR HTA grants awarded to Professor Tim Theologis

Congratulations to Professor Tim Theologis, who has been awarded three NIHR HTA grants to extend research in orthopaedic disorders in children.

Going straight to surgery found to be better than undergoing rehabilitation first for longstanding anterior cruciate ligament injury

New research, funded by the National Institute for Health and Care Research (NIHR), shows initial surgery to be more successful and cost effective than undergoing treatment with rehabilitation first to treat longstanding anterior cruciate ligament injury.

Oxford receives NIHR funding to test anti-TNF on post operative delirium

Researchers at the University of Oxford have been awarded a grant from the National Institute for Health and Care Research (NIHR) to investigate whether anti-tumour necrosis factor (TNF) therapy can reduce or prevent post operative delirium/cognitive deficit.